干细胞治疗急性呼吸窘迫综合征的进展  

Progress of mesenchymal stem/stromal cells therapy in acute respiratory distress syndrome

作　　者：邢学忠[1] 高勇[1] 王海军[1] 曲世宁[1] 黄初林[1] 杨全会[1] 

机构地区：[1]国家癌症中心/中国医学科学院北京协和医学院肿瘤医院重症医学科,北京100021

出　　处：《中国生化药物杂志》2016年第7期22-24,共3页Chinese Journal of Biochemical Pharmaceutics

摘　　要：急性呼吸窘迫综合征(acute respiratory distress syndrome,ARDS)病死率高达40%,多种药物治疗未发现能够改善ARDS的预后。近年来动物研究及离体人肺研究发现间充质干细胞(mesenchymal stem/stromal cells,MSCs)可以增加肺水清除、减轻炎症,对ARDS有一定的疗效。1期临床研究提示间充质干细胞治疗人ARDS是安全的。MSCs治疗人ARDS的一项2期临床试验(NCT01775774)正在进行。尽管MSCs治疗ARDS刚刚起步,基于细胞的干细胞疗法为ARDS的治疗提供了新的希望。本文简要回顾MSCs治疗ARDS的现状,包括MSCs治疗ARDS的动物实验和临床试验,机制和存在的问题。Acute respiratory distress syndrome（ARDS） has a mortality rate over 40%,and many pharmaceutical therapies have not been shown to improve the outcomes of ARDS. In recent years,animal experiments and in vitro human perfused lung experiments demonstrated that mesenchymal stem/stromal cells（MSCs） therapy could increase alveolar fluid clearance,alleviate inflammation. A phase 1 clinical trial validated the safety of MSCs therapy on ARDS patients. An ongoing phase 2 trial（NCT01775774） will determine the effective of MSCs therapy. Although in its beginning period,cell based MSCs therapy provides a promising treatment for ARDS. Here,we briefly review the current status of MSCs therapy for ARDS,including the animal experiments,clinical trials,mechanisms and debates.

关 键 词：急性呼吸窘迫综合症 干细胞疗法 进展 

分 类 号：R563.8[医药卫生—呼吸系统]